Simplifying Complexity, Enabling Breakthroughs

Yes. We maintain direct relationships with many global manufacturers and qualified distributors. We source as direct as feasible for each project and set up new accounts when needed. We do not publish a list. Availability depends on product status and manufacturer policy.

Often yes. Feasibility depends on formulation, presentation, and legal constraints. We assess options and propose the best route, including matched packaging and labeling where possible.

Yes. We deliver to sites in line with protocol and country rules. We support Direct to Patient where allowed and approved by the sponsor and the relevant bodies.

Yes, where licensed and permitted. We store in secure areas, including walk‑in vaults with controlled access, and manage authority interfaces for import and distribution.

Yes. We coordinate third‑country imports for Investigational Medicinal Products with Qualified Person (QP) oversight and required documentation. Scope depends on product, country, and permits.

Where appropriate and permitted. We usually optimize batch sizes to match recruitment and reduce waste.

Yes. We perform market availability checks through our affiliate and partner network and provide validated options. Final availability depends on local law and manufacturer policy.

Yes. We provide study‑specific packaging and labeling, including multilingual content, blinded kits, and country adaptations under GMP‑aligned processes.

Document availability varies by product and manufacturer. Common items include:

• Certificate of Analysis (CoA)
• Certificate of Conformity or Compliance (CoC)
• EU QP certification or batch release statement
• TSE/BSE statements where required
• Safety Data Sheet (SDS)
• Certificate of Origin and transaction documentation where applicable
• Temperature excursion assessment and fit‑for‑use statement (if supported by investigation)
• Manufacturer GMP certificate or license
• Sterility certificate where relevant
• Certificate of a Pharmaceutical Product (CPP) where relevant

Yes. We handle returns, quarantine, and compliant destruction according to sponsor and regulatory requirements.

Ambient, refrigerated, frozen, and ultra‑cold with validated packaging, monitoring, and excursion management.

Lead times vary by product, country, and permits. We provide a project plan with expected timelines after feasibility.

Diseases affecting blood, bone marrow, and the lymphatic system, including both benign and malignant conditions.

Treatment complexity, controlled handling requirements, and patient-specific therapies demand precise coordination and uninterrupted supply.

Conditions affecting the cardiovascular system and metabolic regulation, including chronic diseases such as hypertension, diabetes, and dyslipidemia.

Large patient populations and long treatment durations require stable supply, reimbursement alignment, and adherence-focused delivery models to ensure continuity of care.

Disorders of the central and peripheral nervous system, including rare and degenerative conditions.

Complex therapies, vulnerable patient populations, and specialised handling requirements necessitate controlled access and continuity of care.

Malignant diseases across solid tumors and hematologic cancers.

Treatment involves complex regimens, combination therapies, and strict protocols, requiring coordinated delivery across hospital and specialised care settings.

Disorders of endocrine glands and metabolic systems, including rare and often hereditary conditions requiring lifelong management.

Small patient populations, complex treatment regimens, and continuous monitoring demand highly individualised access pathways and reliable long-term supply.

Diseases caused by bacterial, viral, fungal, or parasitic pathogens, ranging from acute infections to global health threats.

Rapid response, controlled distribution, and coordination with health authorities are critical, particularly in outbreak or resistance-driven scenarios.

Diseases of the gastrointestinal tract and liver, including inflammatory, infectious, and chronic conditions.

Treatment often involves biologics or specialised therapies administered in hospital or infusion settings, requiring coordinated delivery, monitoring, and site alignment.

Diseases affecting the lungs and respiratory system, including chronic and acute conditions.

Treatment often combines pharmaceuticals and devices, requiring coordinated supply, device integration, and long-term patient support.

Diseases of the skin, hair, and nails, ranging from acute conditions to chronic immune-mediated disorders such as psoriasis and atopic dermatitis.

Treatment variability and predominantly outpatient care settings require flexible supply models aligned with prescribing practices and long-term patient adherence.

Psychiatry and Behavioral Disorders

Conditions affecting cognition, mood, and behaviour, often requiring long-term pharmacological and therapeutic management.

Regulatory controls, adherence challenges, and patient monitoring are critical to ensure safe and consistent treatment.

Diseases affecting joints, muscles, bones, and connective tissue, often chronic and progressive.

Long-term biologic therapies and outpatient care models require sustained access, monitoring, and continuity of treatment.

Diseases of the urinary tract and kidneys, spanning acute and chronic conditions.

Treatment pathways often involve both hospital and long-term care settings, requiring flexible and reliable supply models.

Diseases of the eye and visual system, often requiring precision therapies and specialised administration.

Small-volume treatments, sensitive formulations, and strict handling conditions demand accuracy in packaging, delivery, and clinical use.

Conditions affecting the ear, nose, throat, and vestibular system.

Specialised care environments and diverse treatment approaches require adaptable and clinic-aligned delivery models.

Conditions related to reproductive health, fertility, and hormonal balance.

Sensitive therapies, strict timing requirements, and specialised handling demand precise coordination and patient-focused delivery.

Chronic immune-mediated conditions requiring long-term treatment, often with biologic therapies.

Sustained delivery, patient monitoring, and adherence support are essential to maintain treatment effectiveness over time.

Therapies used across acute, inpatient, and emergency care environments.

Unpredictable demand and time-critical treatment needs require rapid access, scalable supply models, and reliable availability under pressure.